<DOC>
	<DOCNO>NCT00726882</DOCNO>
	<brief_summary>The purpose follow-up study evaluate frequency persistence specific viral mutation response treatment ABT-333 ( dasabuvir ) .</brief_summary>
	<brief_title>A Follow-up Assessment Resistance ABT-333 Hepatitis C Virus ( HCV ) -Infected Subjects Who Have Received ABT-333 ABT-333 Studies</brief_title>
	<detailed_description>This Phase 2 , multicenter study conduct HCV-infected participant receive ABT-333 dose level match placebo prior clinical study involve ABTâˆ’333 . Hepatitis C virus ( HCV ) -infected participant receive ABT-333 dose level match placebo Study M10-351 Substudy 2 ( NCT00696904 ; ABT-333 dose duration 2 day ) Study M10-380 ( NCT00851890 ; ABT-333 dose duration 28 day ) eligible . After receive least 1 dose ABT-333 placebo , subject assess participation rollover study ask review inform consent . The day study completion early discontinuation prior ABT-333 clinical study serve baseline assessment . If find participant receive placebo previous ABT-333 clinical study , site instruct discontinue participant study . This study include approximately monthly blood sample collection procedures 48 week , treatment provide time .</detailed_description>
	<criteria>Main Selection Criteria : Subject receive ABT333 match placebo prior clinical study involve ABT333 . The investigator considers subject unsuitable study reason inclusive , limited , failure comply study procedure prior ABT333 clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>HCV Infection</keyword>
</DOC>